Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M

Carte­sian Ther­a­peu­tics, an mR­NA cell ther­a­py biotech, said its lead in­ves­ti­ga­tion­al med­i­cine helped pa­tients with an au­toim­mune con­di­tion that has caught the at­ten­tion of many …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

June Cannabis Sales Pick Up

New Cannabis Ventures offers readers this easy-to-read exclusive summary of BDSA’s monthly cannabis sales data for 11 states. Cannabis sales increased 0.3% sequentially in June

Read More »